ArticleGastroenterology and hepatology from bed to bench2025
Evolving etiologies of liver transplantation: a trend analysis from 2020 to 2024 at the main center of Iran.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to analyze trends in the etiologies of liver transplants at Abu Ali Sina Hospital, Shiraz, Iran, from 2020 to 2024. Background: Liver transplantation (LT) is a crucial treatment for end-stage liver disease (ESLD). Over time, the etiologies leading to LT have evolved due to changes in disease prevalence, advancements in medical treatments, and public health interventions. Methods: Etiologies of LT were categorized into nine groups: acute liver failure, autoimmune disorders, alcoholic steatohepatitis, liver cancer, vascular, metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, metabolic disorders, and others. Trend analysis was performed using Python 3.12 programming language with appropriate libraries. Results: A total of 1579 patients, 59.9% male with a mean age of 45.12 years (SD: 13.52), were analyzed. Autoimmune disorders emerged as the leading cause of LT, increasing from 32.2% in 2020 to 40.6% in 2024 (p-trend = 0.039). Viral hepatitis cases decreased significantly from 18.1% to 3.0% (p-trend = 0.033). Liver cancer became the third leading cause in 2021, replacing viral hepatitis, while MASH consistently remained the second leading cause. Conclusion: The significant shifts in LT etiologies underscore the success of public health interventions in reducing the burden of viral-related ESLD. Additionally, the findings highlight the need for ongoing research into the prevention, early diagnosis, and management of autoimmune liver diseases, MASH, and liver cancer. These findings provide critical insights for clinicians and policymakers to enhance liver disease management and allocate resources effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.